27,529 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 27,529 shares of Medpace Holdings, Inc. for approximately $8.39 million, representing a 0.10% ownership stake after the most recent reporting period.
• Analysts have set a consensus price target of $411.10 for Medpace, with Mizuho raising their price objective to $510.00 while two analysts rated the stock as a sell.
• Medpace's recent quarterly earnings showed a 14.2% revenue increase year-over-year, with the company reporting an EPS of $3.10, exceeding analysts' estimates of $3.00.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 27,529 shares of the company's stock, valued at approximately $8,388,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.10% of Medpace at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MEDP. Whittier Trust Co. boosted its holdings in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after purchasing an additional 35 shares during the last quarter. Colonial Trust Co SC increased its position in shares of Medpace by 150.0% during the 4th quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after purchasing an additional 105 shares during the period. True Wealth Design LLC boosted its stake in shares of Medpace by 52.7% during the 4th quarter. True Wealth Design LLC now owns 258 shares of the company's stock worth $86,000 after acquiring an additional 89 shares in the last quarter. Nemes Rush Group LLC bought a new stake in shares of Medpace during the 4th quarter worth $86,000. Finally, GeoWealth Management LLC boosted its position in shares of Medpace by 27.8% in the fourth quarter. GeoWealth Management LLC now owns 285 shares of the company's stock worth $95,000 after buying an additional 62 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Down 2.3%

Shares of MEDP stock traded down $10.14 during trading hours on Wednesday, hitting $437.78. 508,328 shares of the company were exchanged, compared to its average volume of 716,550. The firm has a fifty day simple moving average of $328.27 and a 200 day simple moving average of $322.97. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $501.30. The stock has a market capitalization of $12.30 billion, a price-to-earnings ratio of 32.55, a P/E/G ratio of 2.82 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter last year, the company posted $2.75 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MEDP. Truist Financial increased their price objective on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. TD Cowen reissued a "sell" rating and set a $366.00 target price (up from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lifted their price objective on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Finally, Barclays boosted their target price on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Medpace currently has a consensus rating of "Hold" and a consensus target price of $406.60.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 41,801 shares of the business's stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the completion of the transaction, the president directly owned 36,503 shares of the company's stock, valued at $16,539,874.33. The trade was a 53.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. This represents a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 112,788 shares of company stock valued at $51,018,354 over the last three months. 20.30% of the stock is currently owned by corporate insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.